248 related articles for article (PubMed ID: 26196151)
1. Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study.
Brauer R; Bhaskaran K; Chaturvedi N; Dexter DT; Smeeth L; Douglas I
PLoS Med; 2015 Jul; 12(7):e1001854. PubMed ID: 26196151
[TBL] [Abstract][Full Text] [Related]
2. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Brauer R; Wei L; Ma T; Athauda D; Girges C; Vijiaratnam N; Auld G; Whittlesea C; Wong I; Foltynie T
Brain; 2020 Oct; 143(10):3067-3076. PubMed ID: 33011770
[TBL] [Abstract][Full Text] [Related]
3. Glitazone use associated with reduced risk of Parkinson's disease.
Brakedal B; Flønes I; Reiter SF; Torkildsen Ø; Dölle C; Assmus J; Haugarvoll K; Tzoulis C
Mov Disord; 2017 Nov; 32(11):1594-1599. PubMed ID: 28861893
[TBL] [Abstract][Full Text] [Related]
4. Does glitazone treatment have a role on the prevention of Parkinson's disease in adult diabetic population? A systematic review.
Meléndez-Flores JD; Millán-Alanís JM; González-Martínez A; Álvarez-Villalobos NA; Estrada-Bellmann I
Metab Brain Dis; 2020 Oct; 35(7):1067-1075. PubMed ID: 32363472
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.
Carta AR; Simuni T
Expert Opin Investig Drugs; 2015 Feb; 24(2):219-27. PubMed ID: 25227476
[TBL] [Abstract][Full Text] [Related]
6. Association of thiazolidinedione with a lower risk of Parkinson's disease in a population with newly-diagnosed diabetes mellitus.
Lin HL; Lin HC; Tseng YF; Chao JC; Hsu CY
Ann Med; 2018 Aug; 50(5):430-436. PubMed ID: 29888974
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence.
Hussain S; Singh A; Baxi H; Taylor B; Burgess J; Antony B
Neurol Sci; 2020 Dec; 41(12):3697-3703. PubMed ID: 32514858
[TBL] [Abstract][Full Text] [Related]
8. Body mass index, diabetes, and the risk of Parkinson's disease.
Jeong SM; Han K; Kim D; Rhee SY; Jang W; Shin DW
Mov Disord; 2020 Feb; 35(2):236-244. PubMed ID: 31785021
[TBL] [Abstract][Full Text] [Related]
9. Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.
Qin X; Zhang X; Li P; Wang M; Yan L; Bao Z; Liu Q
Front Neurol; 2021; 12():678649. PubMed ID: 34349721
[No Abstract] [Full Text] [Related]
10. Effect of lobeglitazone on motor function in rat model of Parkinson's disease with diabetes co-morbidity.
Hassanzadeh K; Rahimmi A; Moloudi MR; Maccarone R; Corbo M; Izadpanah E; Feligioni M
Brain Res Bull; 2021 Aug; 173():184-192. PubMed ID: 34051296
[TBL] [Abstract][Full Text] [Related]
11. Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis.
Zhu Y; Pu J; Chen Y; Zhang B
PLoS One; 2019; 14(10):e0224236. PubMed ID: 31639149
[TBL] [Abstract][Full Text] [Related]
12. Chinese herbal medicine reduced the risk of stroke in patients with Parkinson's disease: A population-based retrospective cohort study from Taiwan.
Lai CY; Chiang JH; Lin JG; Yen HR; Tu CH; Chen YH
PLoS One; 2018; 13(9):e0203473. PubMed ID: 30192890
[TBL] [Abstract][Full Text] [Related]
13. Prediabetes, type 2 diabetes mellitus and risk of Parkinson's disease: A population-based cohort study.
Sánchez-Gómez A; Díaz Y; Duarte-Salles T; Compta Y; Martí MJ
Parkinsonism Relat Disord; 2021 Aug; 89():22-27. PubMed ID: 34216937
[TBL] [Abstract][Full Text] [Related]
14. PPAR-γ: therapeutic prospects in Parkinson's disease.
Carta AR
Curr Drug Targets; 2013 Jun; 14(7):743-51. PubMed ID: 23469878
[TBL] [Abstract][Full Text] [Related]
15. Diabetes preceding Parkinson's disease onset. A case-control study.
D'Amelio M; Ragonese P; Callari G; Di Benedetto N; Palmeri B; Terruso V; Salemi G; Famoso G; Aridon P; Savettieri G
Parkinsonism Relat Disord; 2009 Nov; 15(9):660-4. PubMed ID: 19356970
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone use and Parkinson's disease: a retrospective cohort study in Taiwan.
Wu HF; Kao LT; Shih JH; Kao HH; Chou YC; Li IH; Kao S
BMJ Open; 2018 Aug; 8(8):e023302. PubMed ID: 30158237
[TBL] [Abstract][Full Text] [Related]
17. Statin use and the risk of Parkinson's disease in persons with diabetes: A nested case-control study.
Honkamaa K; Paakinaho A; Tolppanen AM; Kettunen R; Hartikainen S; Tiihonen M
Br J Clin Pharmacol; 2024 Jun; 90(6):1463-1470. PubMed ID: 38477540
[TBL] [Abstract][Full Text] [Related]
18. In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease.
Ridder DA; Schwaninger M
Exp Neurol; 2012 Dec; 238(2):133-7. PubMed ID: 23085103
[TBL] [Abstract][Full Text] [Related]
19. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
20. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.
Normando EM; Davis BM; De Groef L; Nizari S; Turner LA; Ravindran N; Pahlitzsch M; Brenton J; Malaguarnera G; Guo L; Somavarapu S; Cordeiro MF
Acta Neuropathol Commun; 2016 Aug; 4(1):86. PubMed ID: 27535749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
